Skip to content

Efficacy and safety of reverse-c fundoplication in the treatment of hiatal hernia and gastroesophageal reflux disease

Efficacy and safety of reverse-c fundoplication in the treatment of hiatal hernia and gastroesophageal reflux disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125104
Enrollment
Unknown
Registered
2026-05-21
Start date
2026-05-27
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hiatal hernia

Interventions

RC:RC Fundoplication

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75, regardless of gender; 2. Esophageal hiatal hernia was diagnosed by gastroscopy, CT, esophageal barium angiography or high resolution manometry; 3. Presence of typical gastroesophageal reflux disease (GERD) symptoms (heartburn, acid reflux), poor treatment with proton pump inhibitors (PPIs), dependence on PPIs, or reluctance to take long-term medication; 4. One or a combination of the following criteria is met: (1) CT/diaphragmatic esophageal hiatus >= 3 cm on imaging; (2) LES resting pressure (HRM) on high-resolution manometry of the esophagus: = 14.72 points or the number of non-acid reflux is abnormal; (5) Endoscopy indicates gastroesophageal valve GEFV grading Hill grade III or IV; (6) Endoscopy indicates reflux esophagitis LA-B grade and above; 5. The patient or guardian agrees to sign the informed consent form, has good compliance, and cooperates with follow-up.

Exclusion criteria

Exclusion criteria: 1. History of previous esophageal or stomach surgery; 2. Use of mesh during hiatal hernia repair; 3. Presence of surgical contraindications, unable to tolerate surgery or general anesthesia; 4. Confirmed diagnosis of esophageal or gastric malignant tumor; 5. Already diagnosed with severe esophageal motility disorder or experiencing progressive dysphagia, regurgitation of undigested food or liquid, significant weight loss, nighttime cough, with examination confirming severe esophageal motility disorder (such as achalasia, diffuse esophageal spasm); 6. Pregnant or breastfeeding women; 7. Presence of other serious diseases affecting the evaluation of this study, unable to cooperate; 8. Unable to understand the procedures and methods of this clinical study, refuse to participate and refuse to sign the informed consent form;

Design outcomes

Primary

MeasureTime frame
One-year postoperative GERD remission rate;Incidence of serious complications within 90 days after surgery;Incidence of dysphagia at 1 year after surgery;

Secondary

MeasureTime frame
GERD-HRQL score change;GERD-Q score change;Proton pump inhibitor discontinuation rate;

Countries

China

Contacts

Public ContactQiyuan Yao

Huashan Hospital, Fudan University

hs_stevenyao@163.com+86 21 5288 7799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026